Department of Electrical and Computer Engineering, Bradley University, Peoria, IL, 61612, USA.
Innovative Health Strategies, LLC, Peoria, IL, 61614, USA.
Sci Rep. 2021 Dec 31;11(1):24513. doi: 10.1038/s41598-021-04094-x.
Opioid use disorder has been designated a worsening epidemic with over 100,000 deaths due to opioid overdoses recorded in 2021 alone. Unintentional deaths due to opioid overdoses have continued to rise inexorably. While opioid overdose antidotes such as naloxone, and nalmefene are available, these must be administered within a critical time window to be effective. Unfortunately, opioid-overdoses may occur in the absence of antidote, or may be unwitnessed, and the rapid onset of cognitive impairment and unconsciousness, which frequently accompany an overdose may render self-administration of an antidote impossible. Thus, many lives are lost because: (1) an opioid overdose is not anticipated (i.e., monitored/detected), and (2) antidote is either not present, and/or not administered within the critical frame of effectiveness. Currently lacking is a non-invasive means of automatically detecting, reporting, and treating such overdoses. To address this problem, we have designed a wearable, on-demand system that comprises a safe, compact, non-invasive device which can monitor, and effectively deliver an antidote without human intervention, and report the opioid overdose event. A novel feature of our device is a needle-stow chamber that stores needles in a sterile state and inserts needles into tissue only when drug delivery is needed. The system uses a microcontroller which continuously monitors respiratory status as assessed by reflex pulse oximetry. When the oximeter detects the wearer's percentage of hemoglobin saturated with oxygen to be less than or equal to 90%, which is an indication of impending respiratory failure in otherwise healthy individuals, the microcontroller initiates a sequence of events that simultaneously results in the subcutaneous administration of opioid antidote, nalmefene, and transmission of a GPS-trackable 911 alert. The device is compact (4 × 3 × 3 cm), adhesively attaches to the skin, and can be conveniently worn on the arm. Furthermore, this device permits a centralized remotely accessible system for effective institutional, large-scale intervention. Most importantly, this device has the potential for saving lives that are currently being lost to an alarmingly increasing epidemic.
阿片类药物使用障碍已被指定为一种日益严重的流行疾病,仅 2021 年就有超过 100000 人死于阿片类药物过量。由于阿片类药物过量导致的意外死亡人数仍在无情上升。虽然有纳洛酮和纳美芬等阿片类药物解毒剂可用,但必须在关键时间窗口内使用才能有效。不幸的是,阿片类药物过量可能在没有解毒剂的情况下发生,或者可能无人见证,而且过量常伴有认知障碍和意识丧失的快速发作,这可能使患者无法自行使用解毒剂。因此,许多生命因此丧失:(1)没有预料到(即监测/检测到)阿片类药物过量,以及(2)解毒剂既不存在,并且/或者不在有效时间内使用。目前缺乏一种非侵入性的方法来自动检测、报告和治疗此类过量。为了解决这个问题,我们设计了一种可穿戴的按需系统,该系统由一个安全、紧凑、非侵入性的设备组成,该设备可以在无需人工干预的情况下进行监测和有效给药,并报告阿片类药物过量事件。我们的设备的一个新颖特点是一个针存放室,它将针以无菌状态存储,并仅在需要药物输送时将针插入组织。该系统使用微控制器,该微控制器通过反射脉搏血氧仪连续监测呼吸状态。当血氧计检测到佩戴者的血红蛋白饱和度低于或等于 90%时(这表明健康个体即将发生呼吸衰竭),微控制器会启动一系列事件,同时导致皮下给予阿片类解毒剂纳美芬,并传输可通过 GPS 追踪的 911 警报。该设备体积小巧(4×3×3 厘米),可粘贴在皮肤上,方便地佩戴在手臂上。此外,该设备允许建立一个集中的远程可访问系统,以实现有效的机构、大规模干预。最重要的是,该设备有可能拯救目前因日益严重的流行疾病而失去的生命。